PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT02049593 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer
Unspecified Adult Solid Tumor

Interventions

DRUG: PARP inhibitor BMN-673
DRUG: temozolomide
DRUG: irinotecan hydrochloride
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]